Xenetic Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on focused on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company’s proprietary drug development platforms include PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The group’s product candidates include oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer (EC). The firm is based in the United States.